| 摘要 |
[Objectives] To systematically evaluate the efficacy and safety of salmon calcitonin in the treatment of osteoporosis, and to provide reference for clinical salmon calcitonin treatment and improvement of bone pain symptoms of osteoporosis. [Methods] Randomized controlled trials (RCTs) of salmon calcitonin in the treatment of osteoporosis from January 2000 to March 2015 were collected by searching Chinese Biomechanics Literature Database (SinoMed, CBM), China National Knowledge Infrastructure (CNKI), VIP and Wanfang Database. The relevant data of bone pain degree and bone mineral density were extracted to evaluate the methodological quality. Meta-analysis was performed using RevMan 5.1 software. A total of 13 randomized controlled trials involving 1 683 patients were included, including 862 patients in the observation group and 821 patients in the control group. [Results] Meta-analysis showed that salmon calcitonin combined with calcium was better than the control group in improving bone pain symptoms in osteoporosis patients, and the difference was statistically significant [RR=1.84, 95% CI (1.56, 2.18)]. [Conclusions] The salmon calcitonin can significantly improve the bone pain symptoms of the osteoporosis patients, and has no serious adverse reaction. However, due to the small number of studies included in this systematic review and the small sample size, it still needs to be confirmed by high-quality, large sample, multi-center randomized controlled trials. |
